What is the 13F Pro Quality Score for MEDP?

13F Pro ranks Medpace Holdings, Inc. (MEDP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MEDP's current score at https://13fpro.ai/company/MEDP (free sign-up required for the full ranking).

Which hedge funds own the most MEDP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MEDP include BlackRock,, PRICE T ROWE ASSOCIATES /MD/, AQR CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MEDP as soon as new 13F filings post.

Where does 13F Pro source MEDP data?

All Medpace Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Medpace Holdings, Inc. files with the SEC under CIK 1668397. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MEDP in?

Medpace Holdings, Inc. (MEDP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives MEDP's revenue?

Per Medpace Holdings, Inc.'s latest 10-Q filed with the SEC on 2026-07-23, the biggest revenue drivers are: Metabolic ($219.1M); Oncology ($209.4M); Other ($98.3M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/MEDP.

What are MEDP's largest expenses?

Medpace Holdings, Inc.'s latest 10-Q reports these as the largest expense items: Reimbursed out-of-pocket expenses ($303.1M, +27.7% YoY); Direct service costs, excluding D&A ($202.6M, +9.0% YoY); Selling, general and administrative ($48.1M, +3.1% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is MEDP research updated on 13F Pro?

MEDP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Medpace Holdings, Inc.(MEDP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1668397 MEDP stock profile & AI dashboard →

13F Pro Quality Score

76.2/100

Rank #86 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

77.4/100

Profitability

74.8/100

Balance Sheet

98.0/100

Earnings Quality

74.9/100

Free Cash Flow

79.0/100

Institutional Flow

79.1/100

Revenue Scale

68.2/100

Dilution Risk

48.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MEDP Scores 76/100

exact factor attribution · 2026-09-11

MEDP's composite is driven by revenue growth and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+5.5 pts

77th pct

Capital efficiency

+4.8 pts

98th pct

Free cash flow

+4.3 pts

79th pct

Profitability

+3.7 pts

75th pct

Scale

+2.7 pts

68th pct

Earnings quality

+2.5 pts

75th pct

Institutional flow

+1.4 pts

79th pct

Earnings growth

+1.3 pts

76th pct

Shareholder dilution

-0.1 pts

49th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MEDP Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Medpace Holdings, Inc. (MEDP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MEDP at 76.2/100 on a 32-signal composite quality model, placing it at rank #86 of 2,961 stocks — the top 5% of the AI-ranked universe. MEDP scores in the top quartile across balance sheet strength (98.0), institutional flow (79.1), free cash flow (79.0). Shareholder dilution risk is elevated at 48.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Medpace Holdings, Inc. reports quarterly revenue of $707.3M, net income of $121.4M, an operating margin of 20.8%. Top institutional holders of MEDP by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. MEDP trades on the Nasdaq exchange and files with the SEC under CIK 1668397. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MEDP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medpace Holdings, Inc. directly from SEC EDGAR. Medpace Holdings, Inc.'s 13F Pro composite quality score has ranged between 69 and 82 since 2021, currently 76.2 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Medpace Holdings, Inc.

Quirks, history, and lore behind MEDP — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mid-cap · listed on Nasdaq · headquartered in Cincinnati, Ohio.
2
The Numbers
Annual revenue in the range of roughly $2 billion, with operating margins that make most contract-service peers jealous — consistently above 20%.
3
The History
Founded in the 1990s in Cincinnati, it grew by staying laser-focused on one thing: running clinical trials for drug and device makers rather than chasing flashier healthcare businesses.
4
The Secret
It operates as a contract research organization (CRO) — meaning pharmaceutical and biotech companies outsource their Phase I–IV drug development studies entirely to its teams.
5
The Lore
Unlike its giant CRO rivals, this company is famously owner-operated, with management holding a large stake and a reputation for running an unusually lean, no-frills culture that Wall Street has rewarded handsomely.
6
The Giveaway
A Cincinnati-based CRO with the ticker that sounds like a doctor's order — MEDP — and a founder-led identity that makes it the boutique darling of the clinical research outsourcing world.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving MEDP's Business? Latest 10-Q Breakdown

✓ 32/32 datapoints verified

AI-extracted from Medpace Holdings, Inc.'s 10-Q filed 2026-07-23 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue rose 17.2% to $707.3 million on Metabolic, Oncology, CNS and AVAI growth, with net income up to $121.4 million, while backlog grew only 4.9% to $3,014.2 million.

Biggest Revenue Drivers

Metabolic$219.1M

Filing cites growth within the Metabolic therapeutic area versus the prior-year period.

Oncology$209.4M

Filing cites growth within the Oncology therapeutic area versus the prior-year period.

Biggest Revenue Drivers

Total revenue: $707.3M+17.2% YoY

Metabolic$219.1M

Filing cites growth within the Metabolic therapeutic area versus the prior-year period.

Oncology$209.4M

Filing cites growth within the Oncology therapeutic area versus the prior-year period.

Other$98.3M

Central Nervous System$82.9M

Filing cites growth within the Central Nervous System therapeutic area versus the prior-year period.

Cardiology$60.0M

Largest Expense Items

Reimbursed out-of-pocket expenses$303.1M+27.7% YoY

Can fluctuate significantly period to period based on the timing of program initiation and closeout.

Direct service costs, excluding D&A$202.6M+9.0% YoY

Higher personnel costs to support growth in service activities, up $15.1 million.

Selling, general and administrative$48.1M+3.1% YoY

Primarily higher personnel costs of $0.8 million to support growth in service activities.

Depreciation$6.6M-3.3% YoY

Remained relatively consistent with the prior-year quarter.

Margins: Total direct costs rose 19.5% versus 17.2% revenue growth, driven mainly by reimbursed out-of-pocket expenses; income from operations still increased to $146.8 million from $126.3 million.

Watch Items from the Filing

Securities class action (filed April 6, 2026) and a June 22, 2026 derivative suit allege misleading statements on book-to-bill; no liability recognized as loss is not estimable.
Backlog grew just 4.9% to $3,014.2 million versus 17.2% revenue growth; remaining performance obligations fell to $3.5 billion from $3.6 billion.
Related-party revenue fell to $4.7 million from $16.9 million YoY, with CinRx contributing $3.5 million versus $15.1 million.
Repurchased 705,616 shares for $294.7 million in the quarter at an average $417.70; $527.0 million authorization remains, funded from $502.7 million cash and no debt.
Effective tax rate fell to 20.0% from 27.5%, aided by Foreign Derived Deduction Eligible Income and uncertain tax position benefits — a non-operating earnings tailwind.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$707.3M

Net Income

Q2 2026

$121.4M

Free Cash Flow

Q2 2026

$138.1M

Operating Margin

Q2 2026

20.8%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+20.0% YoY

$2.53BFY 2025

FY22 $1.46BFY23 $1.89BFY24 $2.11BFY25 $2.53B

Net Income

+11.6% YoY

$451.1MFY 2025

FY22 $245.4MFY23 $282.8MFY24 $404.4MFY25 $451.1M

Operating Income

+19.7% YoY

$534.9MFY 2025

FY22 $278.7MFY23 $336.8MFY24 $446.9MFY25 $534.9M

EPS (Diluted)

+21.0% YoY

$15.28FY 2025

FY22 $7.28FY23 $8.88FY24 $12.63FY25 $15.28

Total Assets

-6.0% YoY

$1.98BFY 2025

FY22 $1.35BFY23 $1.66BFY24 $2.10BFY25 $1.98B

Total Debt

—FY 2025

FY22 $50.0MFY23 $0.00FY24 —FY25 —

Op. Cash Flow

+17.1% YoY

$713.2MFY 2025

FY22 $388.1MFY23 $433.4MFY24 $608.8MFY25 $713.2M

Free Cash Flow

+19.2% YoY

$681.9MFY 2025

FY22 $351.2MFY23 $396.7MFY24 $572.3MFY25 $681.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.53B +20.0%	$2.11B +11.8%	$1.89B +29.2%	$1.46B +27.8%	$1.14B +23.4%	$925.9M
Net Income	$451.1M +11.6%	$404.4M +43.0%	$282.8M +15.3%	$245.4M +34.9%	$181.8M +25.1%	$145.4M
Operating Income	$534.9M +19.7%	$446.9M +32.7%	$336.8M +20.9%	$278.7M +40.3%	$198.6M +18.9%	$167.0M
EPS (Diluted)	$15.28 +21.0%	$12.63 +42.2%	$8.88 +22.0%	$7.28 +51.4%	$4.81 +25.3%	$3.84
Total Assets	$1.98B -6.0%	$2.10B +26.8%	$1.66B +22.5%	$1.35B -18.5%	$1.66B +19.4%	$1.39B
Total Debt	—	—	$0.00 -100.0%	$50.0M	$0.00	—
Operating Cash Flow	$713.2M +17.1%	$608.8M +40.5%	$433.4M +11.7%	$388.1M +47.4%	$263.3M +1.8%	$258.7M
Free Cash Flow	$681.9M +19.2%	$572.3M +44.2%	$396.7M +13.0%	$351.2M +49.4%	$235.1M +3.4%	$227.3M

AI Insight: MEDP Financial Trends

Revenue growth stalled at $707M after explosive 2025 expansion, but operating margins and cash generation remain robust.

• Revenue accelerated from $533M (Q3 2024) to $708M (Q4 2025), a 33% jump, then flatlined at $707M through Q2 2026.

• Operating margin expanded from 21.0% (Q3 2024) to 20.8% (Q2 2026), sustaining 20%+ levels despite revenue plateau.

• Operating cash flow averaged $182M across last four quarters (Q3 2025–Q2 2026) versus $145M in prior year period.

⚠ Net income volatility: $135M (Q4 2025) fell to $121M (Q2 2026)—fourth consecutive quarter below prior-year peaks.

⚠ Equity rebounded to $598M (Q1 2026) and $434M (Q2 2026) after dipping to $172M (Q2 2025)—capital deployment unclear.

AI Insight: MEDP Ratio Trends

ROIC surged to 94.6% in Q1 2026, but net margins remain volatile and operational leverage has flattened.

• ROIC expanded dramatically from 76.5% in Q1 2025 to 94.6% in Q1 2026, signaling improved capital efficiency.

• ROA climbed steadily from 18.5% in Q3 2024 to 27.4% in Q4 2025, reflecting stronger asset deployment.

• Net profit margin contracted to 17.2% in Q2 2026 from 21.8% in Q4 2024, showing margin compression despite stable operating margins.

⚠ NPM volatility: swung from 21.8% (Q4 2024) to 15.0% (Q2 2025), then rebounded to 19.1% (Q4 2025)—suggests operational headwinds or non-recurring items.

⚠ Operating margin has stalled around 20–21.6% for four consecutive quarters; no expansion trend evident.

Get alerted when MEDP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Medpace Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MEDP

BlackRock, Inc.
$1.3B2,498,248 sh
PRICE T ROWE ASSOCIATES INC /MD/
$1.1B2,069,677 sh
AQR CAPITAL MANAGEMENT LLC
$677.3M1,278,935 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$600.2M1,133,357 sh
VANGUARD CAPITAL MANAGEMENT LLC
$543.8M1,026,820 sh
STATE STREET CORP
$376.5M710,895 sh
GEODE CAPITAL MANAGEMENT, LLC
$376.3M710,465 sh
WASATCH ADVISORS LP
$337.1M636,595 sh
Invesco Ltd.
$306.8M579,241 sh
BAILLIE GIFFORD & CO
$250.6M473,211 sh

Fund	Value	Shares
BlackRock, Inc.	$1.3B	2,498,248
PRICE T ROWE ASSOCIATES INC /MD/	$1.1B	2,069,677
AQR CAPITAL MANAGEMENT LLC	$677.3M	1,278,935
VANGUARD PORTFOLIO MANAGEMENT LLC	$600.2M	1,133,357
VANGUARD CAPITAL MANAGEMENT LLC	$543.8M	1,026,820
STATE STREET CORP	$376.5M	710,895
GEODE CAPITAL MANAGEMENT, LLC	$376.3M	710,465
WASATCH ADVISORS LP	$337.1M	636,595
Invesco Ltd.	$306.8M	579,241
BAILLIE GIFFORD & CO	$250.6M	473,211

Companies Similar to MEDP

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IDXX

IDEXX LABORATORIES INC /DE

AI score

Very similar · 20 shared holders

BAILLIE GIFFORD & CO Clearbridge Investments, LLC Epoch Investment Partners, Inc.

WST

WEST PHARMACEUTICAL SERVICES INC

AI score

Very similar · 17 shared holders

Epoch Investment Partners, Inc.RIVERBRIDGE PARTNERS LLC Boston Trust Walden Corp

RMD

RESMED INC

AI score

Similar quality profile · 19 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Giverny Capital Inc.AMERICAN CAPITAL MANAGEMENT INC

EXEL

EXELIXIS, INC.

AI score

Similar quality profile · 32 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.Stephens Investment Management Group LLC CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

SYK

STRYKER CORP

AI score

Similar quality profile · 15 shared holders

Clearbridge Investments, LLC Boston Trust Walden Corp DF DENT & CO INC

INCY

INCYTE CORP

AI score

Similar quality profile · 16 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Grantham, Mayo, Van Otterloo & Co. LLC abrdn plc

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Similar quality profile · 24 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Clearbridge Investments, LLC FULLER & THALER ASSET MANAGEMENT, INC.

PODD

INSULET CORP

AI score

Similar quality profile · 20 shared holders

BAILLIE GIFFORD & CO Clearbridge Investments, LLC Stephens Investment Management Group LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MEDP on your watchlist

Track score changes the day Medpace Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MEDP a good stock to buy?

13F Pro's AI-powered analysis of Medpace Holdings, Inc. (MEDP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MEDP are available on the MEDP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MEDP is classified as a large company.

Which hedge funds own MEDP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MEDP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medpace Holdings, Inc.'s investment landscape.